Sotatercept
Winrevair (sotatercept) is a protein pharmaceutical. Sotatercept was first approved as Winrevair on 2024-03-26. It is used to treat pulmonary arterial hypertension in the USA. It is known to target inhibin beta A chain.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Winrevair
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Sotatercept
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Winrevair | sotatercept-csrk | Merck & Co | N-761363 RX | 2024-03-26 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| winrevair | Biologic Licensing Application | 2025-09-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary arterial hypertension | — | D000081029 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary arterial hypertension | D000081029 | — | — | — | 6 | 7 | 3 | — | 16 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 3 | 6 | 1 | 1 | 11 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | 2 | 6 | 2 | — | 10 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise therapy | D005081 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | 7 | — | — | — | 7 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 3 | — | — | 1 | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 2 | — | — | — | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 2 | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | 1 | 2 |
| Diamond-blackfan anemia | D029503 | EFO_0004130 | D61.01 | 1 | 1 | — | — | — | 1 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | — | — | — | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sotatercept |
| INN | sotatercept |
| Description | Sotatercept (immunoadhesin) |
| Classification | Protein |
| Drug class | receptor molecules or membrane ligands, natural, modified or modified: transforming growth factor receptors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1001080-50-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743073 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12118 |
| UNII ID | 0QI90BTJ37 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
INHBA
INHBA
Organism
Homo sapiens
Gene name
INHBA
Gene synonyms
NCBI Gene ID
Protein name
inhibin beta A chain
Protein synonyms
Activin beta-A chain, EDF, erythroid differentiation factor, Erythroid differentiation protein, follicle-stimulating hormone-releasing protein, FSH-releasing protein, inhibin beta A subunit, inhibin, beta A (activin A, activin AB alpha polypeptide), Inhibin, beta-1
Uniprot ID
Mouse ortholog
Inhba (16323)
inhibin beta A chain (Q04998)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Winrevair – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 772 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,190 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use